Photo by atikahakhtar from unsplash
Guillain-Barré syndrome (GBS) presents as acute inflammatory demyelinating polyneuropathy, which leads to rapid-onset muscle weakness classically caused by immune-mediated damage to the peripheral nervous system. We report here a case… Click to show full abstract
Guillain-Barré syndrome (GBS) presents as acute inflammatory demyelinating polyneuropathy, which leads to rapid-onset muscle weakness classically caused by immune-mediated damage to the peripheral nervous system. We report here a case of GBS occurring during treatment with nivolumab. Nivolumab is a fully human IgG4 programmed death 1 (PD-1) immune-checkpointinhibitor antibody that selectively blocks the interaction of the PD-1 receptor with its 2 known programmed death ligands, PD-L1 and PD-L2. Nivolumab can thereby restore anticancer immune responses by abrogating PD-1 pathway-mediated T-cell inhibition (1). In addition, we discuss possible underlying disease mechanisms and treatment options.
Journal Title: Acta dermato-venereologica
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!